Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma
BOSTON, June 4, 2023. Servier, a leader in oncology committed to bringing innovative therapies to the patients we serve, today presented results from the pivotal Phase 3 INDIGO clinical trial investigating vorasidenib, an investigational, oral,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 4, 2023 Category: Pharmaceuticals Source Type: clinical trials
New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT ® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated Advanced Non-Small Cell Lung Cancer
CHICAGO, June 4, 2023– The Janssen Pharmaceutical Companies of Johnson& Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT® (amivantamab-vmjw) and lazertinib*, a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 4, 2023 Category: Pharmaceuticals Source Type: clinical trials
Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, June 3, 2023– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI® (teclistamab-cqyv), a first-in-class BCMAxCD3 bispecific... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 3, 2023 Category: Pharmaceuticals Source Type: clinical trials
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
CHICAGO, June 3, 2023– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the investigational bispecific antibody talquetamab in the treatment of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 3, 2023 Category: Pharmaceuticals Source Type: clinical trials
Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
This study is the first to use an adaptive design that tailors treatment in the neoadjuvant/adjuvant setting of patients with HER2-positive early... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 3, 2023 Category: Pharmaceuticals Source Type: clinical trials
Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation) on the Face and Hands of Asian Ethnicity Skins
Conditions: Solar Lentigo; Senile Lentigo Interventions: Device: prototypes 1 everyday; Device: prototypes 1 every week; Device: prototypes 1 every two weeks; Device: prototypes 2 every two weeks; Device: prototypes 3 every two weeks Sponsors: Cryonove Pharma; CEISO Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2023 Category: Research Source Type: clinical trials
Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis
Condition: End Stage Renal Disease on Hemodialysis Intervention: Drug: Difelikefalin Injection Sponsors: Vifor Fresenius Medical Care Renal Pharma; Tigermed Consulting Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2023 Category: Research Source Type: clinical trials
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Condition: Uremic Pruritus Interventions: Drug: Difelikefalin Injection; Drug: Placebo Injection Sponsors: Vifor Fresenius Medical Care Renal Pharma; Tigermed Consulting Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2023 Category: Research Source Type: clinical trials
Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation) on the Face and Hands of Asian Ethnicity Skins
Conditions: Solar Lentigo; Senile Lentigo Interventions: Device: prototypes 1 everyday; Device: prototypes 1 every week; Device: prototypes 1 every two weeks; Device: prototypes 2 every two weeks; Device: prototypes 3 every two weeks Sponsors: Cryonove Pharma; CEISO Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2023 Category: Research Source Type: clinical trials
Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis
Condition: End Stage Renal Disease on Hemodialysis Intervention: Drug: Difelikefalin Injection Sponsors: Vifor Fresenius Medical Care Renal Pharma; Tigermed Consulting Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2023 Category: Research Source Type: clinical trials
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Condition: Uremic Pruritus Interventions: Drug: Difelikefalin Injection; Drug: Placebo Injection Sponsors: Vifor Fresenius Medical Care Renal Pharma; Tigermed Consulting Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2023 Category: Research Source Type: clinical trials
Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation) on the Face and Hands of Asian Ethnicity Skins
Conditions: Solar Lentigo; Senile Lentigo Interventions: Device: prototypes 1 everyday; Device: prototypes 1 every week; Device: prototypes 1 every two weeks; Device: prototypes 2 every two weeks; Device: prototypes 3 every two weeks Sponsors: Cryonove Pharma; CEISO Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2023 Category: Research Source Type: clinical trials
Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis
Condition: End Stage Renal Disease on Hemodialysis Intervention: Drug: Difelikefalin Injection Sponsors: Vifor Fresenius Medical Care Renal Pharma; Tigermed Consulting Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2023 Category: Research Source Type: clinical trials
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Condition: Uremic Pruritus Interventions: Drug: Difelikefalin Injection; Drug: Placebo Injection Sponsors: Vifor Fresenius Medical Care Renal Pharma; Tigermed Consulting Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2023 Category: Research Source Type: clinical trials
Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation) on the Face and Hands of Asian Ethnicity Skins
Conditions: Solar Lentigo; Senile Lentigo Interventions: Device: prototypes 1 everyday; Device: prototypes 1 every week; Device: prototypes 1 every two weeks; Device: prototypes 2 every two weeks; Device: prototypes 3 every two weeks Sponsors: Cryonove Pharma; CEISO Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 2, 2023 Category: Research Source Type: clinical trials
